Yazar "Bilgin, Burak" için listeleme
-
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Bilgin, Burak; Sendur, Mehmet Ali; Yücel, Şebnem; Çelik, Emir; Özyükseler, Deniz Tataroğlu; Ayhan, Murat; Yalçın, Bülent; Avcı, Okan (Springer, 2021)Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
Hizal, Mutlu; Bilgin, Burak; Paksoy, Nail; Acıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Sendur, Mehmet Ali Nahit; İriağaç, Yakup (Springer, 2021)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...